Overview

Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma

Status:
Active, not recruiting

Trial end date:
2023-05-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to use precision medicine in the form of a vaccine, a mutation-derived tumor antigen vaccine (MTA-based vaccine) in combination with standard care treatment of glioblastoma (GBM) and Tumor Treating Fields (TTFields). The study is designed to determine whether this treatment combination is well tolerated and safe.

Phase:

Phase 1

Details

Lead Sponsor:

Adilia Hormigo
Adilia M Hormigo

Collaborator:

NovoCure Ltd.

Treatments:

Carboxymethylcellulose Sodium
Poly I-C
Poly ICLC
Vaccines